Diagnose und Behandlung von Eisenmangel und Anämie bei chronisch entzündlichen Darmerkrankungen. Konsensus der österreichischen Arbeitsgruppe für CED

Zusammenfassung

Eisenmangel mit und ohne Anämie ist ein häufiges Problem bei Patienten mit chronisch entzündlichen Darmerkrankungen (CED) und kann mit einer erheblichen Einschränkung der Lebensqualität und Leistungsfähigkeit verbunden sein. Die Arbeitsgruppe für CED der Österreichischen Gesellschaft für Gatroenterologie und Hepatologie (ÖGGH) erarbeitete 5 Konsensus-Statements zu folgenden Inhalten: Diagnose von Eisenmangel und Anämie, Screening auf Eisenmangel, Behandlung von Eisenmangel und Behandlungsziele. Die klinische Bedeutung der intravenösen Eisensubstitution bei CED in Bezug auf Effektivität und Compliance wurde diskutiert.

Abstract

Iron deficiency with and without anAemia is a common burden of patients with inflammatory bowel diseases (IBD) and has considerable impact on their quality of life and the ability to perform. The IBD working group of the Austrian Society of Gastroenterology and Hepatology developed five consensus statements on the following topics: (i) diagnosis of iron deficiency and (ii) anaemia, (iii) screening of iron deficiency, (iv) treatment of iron deficiency and (v) therapeutic goals. The clinical importance of intravenous iron replacement therapy in IBD with regard to effectiveness and compliance was discussed.

Colitis ulcerosa - extraintestinale Manifestation - Morbus Crohn - chronisch entzündliche Darmerkrankung - Eisenmangel

ulcerative colitis - extraintestinal manifestations - Crohn’s disease - inflammatory bowel disease - Iron deficiency

Literatur

• 1 Gasche C. Anemia in IBD: the overlooked villain.  Inflamm Bowel Dis. 2000;  6 142-150
• 2 Gasche C, Lomer M C, Cavill I et al. Iron, anaemia, and inflammatory bowel diseases.  Gut. 2004;  53 1190-1197
• 3 Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn’s disease.  Aliment Pharmacol Ther. 2006;  24 1507-1523
• 4 Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature.  Am J Med. 2004;  116 (Suppl 7A) 44S-9S
• 5 Weiss G, Gasche C. Pathogenesis and treatment of anemia in inflammatory bowel disease.  Haematologica. 2010;  95 175-178
• 6 Gasche C, Berstad A, Befrits R et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases.  Inflamm Bowel Dis. 2007;  13 1545-1553
• 7 WHO, UNICEF, and UNU .Iron Deficiency Anemia: Assessment, Prevention and Control. Report of a joint WHO/UNICEF/UNU consultation. Geneva: World Health Organization; 1998 Conference Proceeding
• 8 Blanc B, Finch C A, Hallberg L et al. Nutritional anaemias. Report of a WHO Scientific Group.  WHO Tech Rep Ser. 1968;  405 1-40
• 9 Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration?.  Blood. 2006;  107 1747-1750
• 10 Beutler E, Felitti V J, Koziol J A et al. Penetrance of 845G → A (C282Y) HFE hereditary haemochromatosis mutation in the USA.  Lancet. 2002;  359 211-218
• 11 Waalen J, Felitti V, Gelbart T et al. Penetrance of hemochromatosis.  Blood Cells Mol Dis. 2002;  29 418-432
• 12 Hollowell J G, Assendelft O W, Gunter E W et al. Hematological and iron-related analytes – reference data for persons aged 1 year and over: United States, 1988 – 94.  Vital Health Stat. 2005;  11 1-156
• 13 Gomollon van F, Gisbert J P. Anemia and inflammatory bowel diseases.  World J Gastroenterol. 2009;  15 4659-4665
• 14 Weiss G, Goodnough L T. Anemia of chronic disease.  N Engl J Med. 2005;  352 1011-1023
• 15 Semrin G, Fishman D S, Bousvaros A et al. Impaired intestinal iron absorption in Crohn’s disease correlates with disease activity and markers of inflammation.  Inflamm Bowel Dis. 2006;  12 1101-1106
• 16 Nemeth E, Tuttle M S, Powelson J et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization.  Science. 2004;  306 2090-2093
• 17 Theurl I, Aigner E, Theurl M et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications.  Blood. 2009;  113 5277-5286
• 18 Busbridge M, Griffiths C, Ashby D et al. Development of a novel immunoassay for the iron regulatory peptide hepcidin.  Br J Biomed Sci. 2009;  66 150-157
• 19 Hansen T M, Hansen N E, Birgens H S et al. Serum ferritin and the assessment of iron deficiency in rheumatoid arthritis.  Scand J Rheumatol. 1983;  12 353-359
• 20 Bartels U, Pedersen N S, Jarnum S. Iron absorption and serum ferritin in chronic inflammatory bowel disease.  Scand J Gastroenterol. 1978;  13 649-656
• 21 Schaefer R M, Schaefer L. Hypochromic red blood cells and reticulocytes.  Kidney Int Suppl. 1999;  69 S44-S48
• 22 Bermejo F, Garcia-Lopez S. A guide to diagnosis of iron deficiency and iron deficiency anemia in digestive diseases.  World J Gastroenterol. 2009;  15 4638-4643
• 23 Devalia V. Diagnosing vitamin B-12 deficiency on the basis of serum B-12 assay.  BMJ. 2006;  333 385-386
• 24 Bruner A B, Joffe A, Duggan A K et al. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls.  Lancet. 1996;  348 992-996
• 25 Erichsen K, Hausken T, Ulvik R J et al. Ferrous fumarate deteriorated plasma antioxidant status in patients with Crohn disease.  Scand J Gastroenterol. 2003;  38 543-548
• 26 Erichsen K, Ulvik R J, Grimstad T et al. Effects of ferrous sulphate and non-ionic iron-polymaltose complex on markers of oxidative tissue damage in patients with inflammatory bowel disease.  Aliment Pharmacol Ther. 2005;  22 831-838
• 27 De Silva A D, Tsironi E, Feakins R M et al. Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trial.  Aliment Pharmacol Ther. 2005;  22 1097-1105
• 28 Seril D N, Liao J, West A B et al. High-iron diet: foe or feat in ulcerative colitis and ulcerative colitis-associated carcinogenesis.  J Clin Gastroenterol. 2006;  40 391-397
• 29 Werner T, Wagner S J, Martinez I et al. Depletion of luminal iron alters the gut microbiota and prevents Crohn’s disease-like ileitis.  Gut. 2011;  60 325-333
• 30 Silva A D, Tsironi de E, Feakins R M et al. Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trial.  Aliment Pharmacol Ther. 2005;  22 1097-1105
• 31 Rimon E, Kagansky N, Kagansky M et al. Are we giving too much iron? Low-dose iron therapy is effective in octogenarians.  Am J Med. 2005;  118 1142-1147
• 32 Zlotkin S, Arthur P, Antwi K Y et al. Randomized, controlled trial of single versus 3-times-daily ferrous sulfate drops for treatment of anemia.  Pediatrics. 2001;  108 613-616
• 33 Schreiber S, Howaldt S, Schnoor M et al. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease.  The New England Journal of Medicine. 1996;  334 619-623
• 34 Schroder O, Mickisch O, Seidler U et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease – a randomized, controlled, open-label, multicenter study.  Am J Gastroenterol. 2005;  100 2503-2509
• 35 Kulnigg S, Stoinov S, Simanenkov V et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.  Am J Gastroenterol. 2008;  103 1182-1192
• 36 Lindgren S, Wikman O, Befrits R et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind, multicentre study.  Scand J Gastroenterol. 2009;  44 (7) 838-895
• 37 Bayraktar U D, Bayraktar S. Treatment of iron deficiency anemia associated with gastrointestinal tract diseases.  World J Gastroenterol. 2010;  16 2720-2725
• 38 Wells C W, Lewis S, Barton J R et al. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients.  Inflamm Bowel Dis. 2006;  12 123-130
• 39 Gisbert J P, Gomollon F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease.  Am J Gastroenterol. 2008;  103 1299-1307
• 40 Kulnigg S, Teischinger L, Dejaco C et al. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment.  Am J Gastroenterol. 2009;  104 1460-1467
• 41 Evstatiev R, Marteau P, Iqbal T et al. Efficacy and safety of standardised ferric carboxymaltose doses vs. individually calculated iron sucrose doses for IBD-associated iron deficiency anaemia: A multicentre, randomised controlled trial.  Gut. 2010;  59 A-5075
• 42 Koutroubakis I E, Oustamanolakis P, Karakoidas C et al. Safety and Efficacy of Total-Dose Infusion of Low Molecular Weight Iron Dextran for Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease.  Dig Dis Sci. 2010;  55 (8) 2327-2331
• 43 Lyseng-Williamson K A, Keating G M. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.  Drugs. 2009;  69 739-756
• 44 Ganzoni A M. Intravenous iron-dextran: therapeutic and experimental possibilities.  Schweiz Med Wochenschr. 1970;  100 301-303
• 45 Ali M, Rigolosi R, Fayemi A O et al. Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy.  Lancet. 1982;  1 652-655
• 46 Besarab A, Bolton W K, Browne J K et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.  N Engl J Med. 1998;  339 584-590
• 47 Locatelli F, Pisoni R L, Combe C et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS).  Nephrol Dial Transplant. 2004;  19 121-132
• 48 Michael B, Coyne D W, Fishbane S et al. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran.  Kidney Int. 2002;  61 1830-1839
• 49 Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia.  Lancet. 2007;  369 1502-1504
• 50 Chertow G M, Mason P D, Vaage-Nilsen O et al. Update on adverse drug events associated with parenteral iron.  Nephrol Dial Transplant. 2006;  21 378-382
• 51 Bailie G R, Clark J A, Lane C E et al. Hypersensitivity reactions and deaths associated with intravenous iron preparations.  Nephrol Dial Transplant. 2005;  20 1443-1449
• 52 Weiss G, Gordeuk V R. Benefits and risks of iron therapy for chronic anaemias.  Eur J Clin Invest. 2005;  35 (Suppl 3) 36-45
• 53 Sazawal S, Black R E, Ramsan M et al. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: community-based, randomised, placebo-controlled trial.  Lancet. 2006;  367 133-143
• 54 Carrier J, Aghdassi E, Platt I et al. Effect of oral iron supplementation on oxidative stress and colonic inflammation in rats with induced colitis.  Aliment Pharmacol Ther. 2001;  15 1989-1999
• 55 Seril D N, Liao J, Ho K L et al. Dietary iron supplementation enhances DSS-induced colitis and associated colorectal carcinoma development in mice.  Dig Dis Sci. 2002;  47 1266-1278
• 56 Seril D N, Liao J, Yang C S et al. Systemic iron supplementation replenishes iron stores without enhancing colon carcinogenesis in murine models of ulcerative colitis: comparison with iron-enriched diet.  Dig Dis Sci. 2005;  50 696-707
• 57 Carrier J, Aghdassi E, Cullen J et al. Iron supplementation increases disease activity and vitamin E ameliorates the effect in rats with dextran sulfate sodium-induced colitis.  J Nutr. 2002;  132 3146-3150
• 58 Kabat G C, Miller A B, Jain M et al. A cohort study of dietary iron and heme iron intake and risk of colorectal cancer in women.  Br J Cancer. 2007;  97 118-122
• 59 Cross A J, Gunter M J, Wood R J et al. Iron and colorectal cancer risk in the alpha-tocopherol, beta-carotene cancer prevention study.  Int J Cancer. 2006;  118 3147-3152
• 60 Senesse P, Meance S, Cottet V et al. High dietary iron and copper and risk of colorectal cancer: a case-control study in Burgundy, France.  Nutr Cancer. 2004;  49 66-71
• 61 Kato I, Dnistrian A M, Schwartz M et al. Iron intake, body iron stores and colorectal cancer risk in women: a nested case-control study.  Int J Cancer. 1999;  80 693-698
• 62 Seril D N, Liao J, West A B et al. High-iron diet: foe or feat in ulcerative colitis and ulcerative colitis-associated carcinogenesis.  J Clin Gastroenterol. 2006;  40 391-397
• 63 Lakatos L, Mester G, Erdelyi Z et al. Risk factors for ulcerative colitis associated colorectal cancers in a Hungarian cohort of ulcerative colitis patients.  Orv Hetil. 2006;  147 175-181
• 64 Stein J, Hartmann F, Dignass A U. Diagnosis and management of iron deficiency anemia in patients with IBD.  Nat Rev Gastroenterol Hepatol. 2010;  7 599-610